Studie SPARCL – the Stroke Prevention by Aggressive Reduction in Cholesterol Levels: commentary
Authors:
H. Rosolová
Authors‘ workplace:
II. interní klinika LF UK a FN Plzeň
; Centrum preventivní kardiologie
Published in:
Kardiol Rev Int Med 2006, 8(4): 208-210
Category:
Editorial
Overview
The author in her paper reports on the objectives, results and outcomes of a prospective, randomised, placebo-controlled SPARCL study and she comments on the study. Patients aged over 18 with underwent ischemic or haemorrhagic CVD (cerebrovascular disease) were incorporated in the study. The aim of the study was to find out whether statins decrease the risk of CVD also in patients after CVD or a transient cerebral ischemic attack. The author observes that despite the limitations of the SPARCL study (with respect to the heterogeneity of CVD and the heterogeneity of patients in terms of the whole cardiovascular risk) its results and further analyses of sub-groups of the study will become a further enrichment of secondary prevention of primarily ischemic CVDs.
Keywords:
SPARCL– CMP – statin – LDL-cholesterol – TIA
Sources
1.The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. N Engl J Med 2006; 355: 549-559.
2.Amarenco P, Labreuche J, Lavallée P et al. Statins in stroke prevention and carotid atherosclarosis: systematic review and meta-analysis. Stroke 2004; 35: 2902-2909.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2006 Issue 4
Most read in this issue
- Pacemaker automatic functions
- Measurement of heart stability
- Treatment of hypertension in chronic renal insufficiency
- New antiarrhythmic drugs in treatment of atrial fibrillation